Lixte Biotechnology Holdings Inc
8640
Company Profile
Business description
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
Contact
433 Plaza Real
Suite 275
Boca RatonFL33432
USAT: +1 631 830-7092
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
stocks
SpaceX jumps 19% in debut, but hurdles lie ahead
Pre-IPO holders could start selling later this summer, and earnings will be an important test.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.00 | 14.60 | 0.16% |
| CAC 40 | 8,384.01 | 33.14 | 0.40% |
| DAX 40 | 24,894.01 | 258.71 | 1.05% |
| Dow JONES (US) | 51,671.03 | 468.77 | 0.92% |
| FTSE 100 | 10,430.62 | 41.10 | -0.39% |
| HKSE | 24,842.67 | 124.57 | 0.50% |
| NASDAQ | 26,683.94 | 795.10 | 3.07% |
| Nikkei 225 | 69,317.50 | 3,297.46 | 4.99% |
| NZX 50 Index | 13,360.59 | 33.28 | -0.25% |
| S&P 500 | 7,554.29 | 122.83 | 1.65% |
| S&P/ASX 200 | 8,914.00 | 7.00 | 0.08% |
| SSE Composite Index | 4,096.47 | 64.96 | 1.61% |